Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind placebo-controlled randomized withdrawal study of XG005 for cancer-induced bone pain
CTR20232870Phase 2Active
- Sponsor
- Changyu Pharma
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of naproxen etemesil in bone metastasis pain (CIBP), sponsored by Changyu Pharma. Started Jan 2024; status: active.
02
Drugs
naproxen etemesil
03
Conditions
bone metastasis pain (CIBP)
Beyond the preview
Go deeper on CTR20232870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232870.